Drug Profile
Research programme: immunotherapies and vaccines - Scorpius Holdings
Alternative Names: Anti-TLIA - NightHawk Biosciences; Anti-TNFRSF25 - Heat Biologics; Fc-OX40L; HS 310 - NightHawk Biosciences; HS-120; HS-210; HS-310; HS-HCV; HS-HIV; HS-HIV/SIV; HS-HIV1; HS-O1; HS-P1; IN-A1; Inhibicor; MedicorLatest Information Update: 09 Feb 2024
Price :
$50
*
At a glance
- Originator Heat Biologics
- Developer Heat Biologics; Scorpius Holdings
- Class AIDS vaccines; Antibodies; Cancer vaccines; Cell therapies; Heat shock proteins; Immunoglobulin fusion proteins; Tumour cell vaccines
- Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunostimulants; Tumour necrosis factor ligand superfamily member 15 inhibitors; Tumour necrosis factor member 25 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Asthma; Autoimmune disorders; Hepatitis C; HIV-1 infections; Transplant rejection